Информация к новости
  • Просмотров: 8510
  • Автор: admin
  • Дата: 29-09-2014, 23:31
29-09-2014, 23:31

Feasibility of Alexander Cherkasky’s Inventions

Category: Blogs

Feasibility of Alexander Cherkasky’s Inventions of Novel Antiautoimmune and Anticancer Fusion Proteins and Technologies for Fast, Simple and Inexpensive DNA and Complete Genome Sequencing
Alexander Cherkasky

Email: alexcherkasky@googlemail.com

- I, Alexander Cherkasky, am award-winning and media-highlighted
biologist (finished the Heinrich-Heine-University of Dusseldorf) and
inventor of new causal therapies, cures for cancer, Alzheimer’s
disease, autoimmune diseases such as multiple sclerosis and diabetes,
new technologies for rapid, low-cost DNA sequencing (for personalized
medicine, and preferable sequencing of genomes of marine organisms and
useful plants), as well as I have inventions of new materials,
diagnostic, test and control systems and lubricants.

- I am owner of 8 German patents, I got them without a patent lawyer
and have 4 US patent applications, 4 international patent applications
and over 30 German patent applications.

- In 1999 and 2000, as student at Goethe-Gymnasium in Dusseldorf, I
partaked in scientific competition Jugend forscht “Youth researches”
with theoretical problem solutions, i.e. inventions of cures for
Alzheimer’s disease, autoimmune diseases and cancer.

- Adjudicators of the “Youth researches” stated in 1999 and 2000 that
I do not have results of clinical studies (it was a cynical
requirement from a school student) and that I am still student at
school, I shall do Abitur (finish school) and then make Vordiplom and
Diplom (finish University). My status was considered also as reason
for a denial of joint commercialization through joint company
foundation or licensing.

- The inventions I presented on “Youth researches” in 1999 and 2000
evoked interest of media and about me and inventions of mine reported
known media including Stern (The Star), Bild der Wissenschaft (Picture
of Science), Rheinische Post (Rhein Post), Westdeutsche Zeitung
(Westgerman Newspaper), Neue Rhein Zeitung (New Rhein Newspapre) and
other media.

- In 2003 I partaked on the international competition of inventors
IENA (Ideas-Inventions-New Products) in Nuremberg and won bronze medal
and got the honorary certificate for my invention of novel anticancer
fusion proteins. IENA is the largest international inventors
competition in Germany already over 60 years.

- You will find my economic proposals, including establishing the
Inventions Implementation System for dynamic problem solutions on my
blog: http://cherkaskysneweconomicmodel.blogspot.com/. This system
shall proof and create solutions for problems of people and work
independently from status of inventors and in addition to firms and
academic and research organizations.
These proposals concern all people, especially because everybody could
need inventive, innovative biomedical help in order to heal, to treat
a disease causally.

- By doing searches (novelty searches for new inventions) I found,
that several various inventions of mine were successfully
experimentally implemented and confirmed, i.e. the feasibility and
perspectives of my inventions, (i.e. inventions for which I have
clearly documented priority) especially of cures for autoimmune
diseases and cancer and inventions for fast, simple and inexpensive
DNA sequencing, were clearly demonstrated by other scientists.

1. The German and American company Micromet (NASDAQ: MITI), which was
sold to Amgen, has experimentally confirmed my prior inventions of
anticancer fusion proteins and my invention of the fusion proteins
against autoimmune diseases (so called Fc-Autoantigen Fusion Proteins
(against multiple sclerosis and diabetes), e.g. Fc-AchR against
Myasthenia gravis). Micromet ignored my published comments on Google
Finance, in Discussion Group about Micromet. Please see the following




Micromet got income through selling stocks and licenses.
Micromet’s issued by error of examiner Mertz US patent US7323440 (each
US patent issued by error of examiner can be invalidated/rejected
after reconsideration or reexamination of the United States Patent and
Trademark Office (USPTO)) (Filed: February 12, 2003, filed in the US:
May 23, 2005 (after publication of my DE10160248 in 2003), claiming
foreign priority of February 13, 2002, US patent issued: January 29,
2008) is not new because of my prior DE10160248 (Filed: December 07,
2001 and published on July 26, 2003). The antiautoimmune cure formula
Fc-Autoantigen, e.g. Fc-AchR is identical in my prior document
DE10160248 and in Micromet’s US7323440. In example 20 of US7323440 is
stated “Inventive, Illustrative Fusion Protein AchR-Fc”, examples
19-24 concern feasibility of AchR-Fc and about feasibility is stated
in example 24: “Antibody titers against AchR were significantly
reduced in those groups of animals treated with the recombinant
AchR-Fc protein suggesting a depletion of autoreactive B cells
directed against AchR.” My inventions of antiautoimmune proteins with
the general formula Fc-Autoantigen, covered in my prior DE10160248,
which Micromet wanted to steal in his issued by error of examiner
Prema Mertz US patent 7323440 include:

1. Fc-AchR against Myasthenia gravis,
2. Fc-MBP against Multiple Sclerosis,
3. Fc-GAD against Diabetes mellitus,
4. Fc-insulin receptor against Diabetes mellitus,
5. Fc-an elected histone protein against SLE (Systemic Lupus Erythemathosus),
6. Fc-an elected ribonucleoprotein against SLE,
7. Fc-DNA-binding domain (DBD) complexed with DNA against SLE,
8. Fc-RNA-binding domain (RBD) complexed with RNA against SLE,
9. Fc-DBD (DNA-binding domain) against SLE,
10. Fc-RBD (RNA-binding domain) against SLE,
11. Fc-TSHR against Basedow disease,
12. Fc-Desmoglein 1 against Pemphigus foliaceus (autoimmune skin disease),
13. Fc-Desmoglein 3 against Pemphigus vulgaris (autoimmune skin disease),
14. Fc-BP 180 against Bullous Pemphigoid (autoimmune skin disease),
15. Fc-collagen-Type-7 against Epidermolysis bullosa aquesita
(autoimmune skin disease),
16. Fc-non-collagenous domain of basal membrane collagen-type 4
against Goodpasture syndrome,
17. Fc-HSP against rheumatoid arthritis,
18. Fc-Integrin gpIIb:IIIa against autoimmune thrombopenia,
19. Fc-a Rhesus antigen against hemolylic anemia, and
20. Fc-I-Antigen against hemolytic anemia.

The anticancer (antileukemia) drug candidate “Blinatomumab” of
Micromet covered by US7635472, US7235641, US20070249529, US20090291072
and US20090022738 is not inventive because of my prior DE10162870
(Filed: December 20, 2001), DE19925052 (Filed: June 01, 1999),
DE10161899 (Filed: December 17, 2001) and DE10161738 (Filed: December
15, 2001) covering anticancer fusion proteins. The novel (single
chain) fusion proteins covered by my DE10162870 “Fusion Proteins
against B Cell Tumors” bind both T cells and (preferably) B cells (or
other cells) and direct T cells against B cells (or other cells). This
my patent application DE10162870 was rejected by examiner Christa
Pitsch-Machacek (German Patent and Trademark Office, Deutsches Patent-
und Markenamt, DPMA), and this examiner Pitsch-Machacek was also
examiner for Micromet and its research director Patrick Baeuerle. Dr.
Pitsch-Machacek considered German patent applications DE60203324,
DE69911793, DE69909459 and DE69233068 of Micromet and DE4311835 of
Patrick Baeuerle. Also my German patent application DE10160248
covering fusion proteins with formula Fc-Autoantigen against
autoimmune diseases was also rejected by examiner Pitsch-Machacek.
This Pitsch-Machacek rejection of my DE10162870 covering anticancer
fusion proteins and DE10160248 (covering my antiautoimmune fusion
proteins) helped Micromet to commercialize my anticancer and
antiantoimmune inventions, i.e. inventions I have clearly documented
priority. Paradoxingly, the current President of the German Patent and
Trademark Office Rudloff-Schäffer stated, that she investigated this
case and trust Pitsch-Machacek whereby Pitsch-Machacek assured
Rudloff-Schäffer, that Pitsch-Machacek does not know Micromet. If
Rudloff-Schäffer would really investigate this case, she would find,
that Pitsch-Machacek was examiner for Micromet and Baeuerle.

2. The American company Halcyon Molecular (mentioned in the article of
Eric Schadt (Nr. 43), in the list of references in the article “DNA
Sequencing” in Wikipedia) is based on my German patent DE19937512 for
fast genome sequencing and this my patent was cited in the key US
patent US8153438 (my patent was cited in references as foreign patent
document and in other references) of Halcyon Molecular, but this
company does not have priority, and this US patent of Halcyon
Molecular is not new and not inventive.

Halcyon Molecular did referenced my German patent DE19937512, but did
not explained the difference between my patent DE19937512 and their
issued by error of examiner patent US8153438 that would make the
patent of Halcyon Molecular new and inventive.

In this US patent US8153438 is stated, that Richard Feynman dreamed in
1959 about direct researching DNA by using electron microscopy. 20
years later, in 1979 F.P. Ottensmeyer stated that an easy and accurate
reading from a single molecule was not possible, because of the
uncontrollable placing of DNA. And also 20 years later, in 1999 I
proposed the optimal solution in my patent DE19937512.

In this patent DE19937512 I proposed the combination of controllable
placing, stretching (extending, aligning, elongating, straightening)
DNA (whereby stretching DNA is combined with DNA immobilization) and
sequencing by electron microscopy. Please see the link to the issued
by error of examiner US patent US8153438 of Halcyon Molecular:


My German patent DE19937512 (also Fig. 6) is also the basis for
non-destructive sequencing by tip microscopy (including multiple tip
or multiple edge nano-knife edge probes, (multiple nano-knife edge
microscopy)) and electron microscopy developed by American firms Reveo
(Dr. Sadeg Faris) and ZS Genetics.

Michael Metzger stated in his review “Sequencing technologies – the
next generation” (Nature Reviews Genetics 11, 31-46 (January 2010):
“Demand has never been greater for revolutionary technologies that
deliver fast, inexpensive and accurate genome information.”

Also American inventor R. Bension mentioned me and my German patent
DE19937512 for fast genome sequencing in his US patent US7163658. This
his US patent was basis for his research published in Small
(B.A.Ashcroft et al “An AFM/Rotaxane Molecular Reading Head for
Sequence-Dependent DNA Structures” Small 2008, 4, No. 9, 1468-1475).

William Roy III Glover (ZS Genetics Inc.) (in his US patent
application US20060029957 “Systems and methods of analyzing nucleic
acid polymers and related components”, filed: July 14, 2005 and
claiming priority of July 14, 2004 as well as in his issued by error
of examiners US patents US7604942, US7604943, US7291468, US7291467,
US7288379 and US patent applications US20100105055, US20080227095,
US20080199871, US20070190557, US20070134699, US20060024717 and
US20060024718) discloses sequencing by electron microscopy. My prior
German patent DE19937512 “Method and device for rapid genome
sequencing by stretching/straightening DNA” (Filed: August 09, 1999,
published as patent application: February 15, 2001 and published as
patent: August 24, 2006) describes fixing of DNA sequence(s) to
substrate, stretching/straightening DNA (including DNA immobilization)
and sequencing by microscopy, especially electron microscopy or other
physical, optical methods (for example 0018 and claim 1 of the patent
DE19937512). Because of this my patent DE19937512, US patent
applications of Nagayama US20020086317 and US20070038261 are not

Ying-Ja Chen, Eric E. Roller and Xiaohua Huang (in their article „DNA
sequencing by denaturation: experimental proof of concept with an
integrated fluidic device”, Lab Chip, 2010, 10, 1153
D0I:10.1039/b921417h, (published online 2010 February 9) and published
in final edited form as: Lap Chip. 2010 May 7; 10(9): 1153-1159)
confirmed feasibility of my invention of rapid, simple and
low-cost/inexpensive DNA sequencing by denaturation. My German patent
DE102008037890 “Method and Device for Sequence Analysis of Nucleic
Acids” (Filed: August 15, 2008, published: April 08, 2010) discloses
the invention of DNA sequencing by denaturation/unwinding (claim 1b)
and detection by using optical methods including spectral analysis and
microscopy (claim 1c). Denaturation occurs through heating or
denaturating substances (claim 6c and 6e). Sequencing by denaturation
and renaturation is also disclosed in claim 3. The combination of
denaturation of double-stranded DNA preferably by heating and
sequencing by using optical methods including microscopy was also
disclosed in the claims 1, 2 and 9 of my German patent application
DE19937512 A1 for fast genome sequencing.

Kyohei Terao, Masao Washizu and Hidehiro Oana (in their article
“On-site manipulation of single chromosomal DNA molecules by using
optically driven microstructures”, first published in Lab on a Chip as
an advance article on the web 23 rd June 2008, (Lab Chip, 2008, 8,
1280-1284)) described controlled DNA winding around one bobbin or two
bobbins and confirmed feasibility of my invention. My prior German
patent DE19929530 “Method and device for fast genome sequencing”
(filed: June 28, 1999, published as patent application: January 04,
2001 and published as patent: May 24, 2006) discloses the picking up
DNA and controlled (controllable) DNA winding around the bobbin or
bobbins (for example claim 1 of my patent DE19929530). Please see my
blog http://alexandercherkasky.blogspot.com/.

3. The Nobel Laureate Joshua Lederberg (please see the blog:
http://alexandercherkasky.blogspot.com/) (in his US20040033584
“Therapeutic use of particles displaying pathogen-specific moiety”
(claiming priority of December 21, 2002, i.e. after publication of my
prior DE19818938 on November 04, 1999) and the company Vector Logics
(David Curiel in WO2006119449, Filed: May 04, 2005) confirmed my
anticancer invention of genetically modified anticancer viruses with
antibodies or receptors for recognizing cancer cells, which was
described in my prior patent application DE19818938 (filed in 1998).

4. The confirmation of my anticancer fusion proteins (described in my
prior DE19925052, DE10162870, DE10161899 and DE10161738) done by Anke
Kretz-Rommel (in WO2007048022, filed: October 21, 2005) at the US firm
Alexion is described on my blog: http://cherkaskyoffers.blogspot.com/.

Thus the inventions I propose (and proposed as school student) are
implemented and confirmed (the feasibility was clearly demonstrated).

I have 4 US patent applications (US20090070900, US20080242565,
US20080200652 and US20070106066) covering new fusion proteins against
cancer and inflammations and for fast diagnosis of various diseases as
well as covering new materials, labels and new lubricants.

Google proposed search for Novel Cherkasky fusion proteins (by
entering my name in Google search) and Google published my US patent
application US20080200652 for Novel Cherkasky antibody-binding
proteins (which are blockbusters in biotechnology, because these my
fusion proteins can be used both for therapy and diagnosis and can
enhance, boost therapeutic effects of available antibodies) on Google
patents and other my US patent applications on the Google service
Patent Alert. Please see the following links:




My German patent documents were basis for other scientists who
referenced/cited these my patent documents in their US patents
(US7902156 and US7557182 cited my DE19953696 covering cures for
Alzheimer’s disease, other neurological diseases and cancer, US
7999073 cited my German patent DE19925052 covering novel
pharmaceutical preparations especially for use in gene therapy,
US8034766 referenced my DE19822406 (presented by “Youth researches” in
1999 and highlighted by Stern (The Star)) against prions and for prion
decontamination (the Assignees for the US patent US8034766 for prion
decontamination are E I du Pont de Nemours and Company and University
College London) and as mentioned above, the US patents US8153438 and
US7163658 referenced my German patent DE19937512 for fast DNA
sequencing, whereby the US patent US8153438 of Halcyon Molecular for
fast sequencing is not new and not inventive because of my German
patent DE19937512).
My patent application DE19822406 (filed: May 12, 1998 and published:
November 25,1999) covers protease-(containing) fusion proteins for
specific elimination (selective proteolysis) of pathogenic proteins
such as prions, amyloid proteins, oncoproteins, immune complexes and
other dangerous proteins. It means that my DE19822406 discloses cures
for nephritis (glomerulonephritis), arthritis, uvetitis, vasculitis,
other immune complex and autoimmune and inflammatory diseases, prion
diseases, cancer and Alzheimer’s disease.

Alexander Cherkasky

Email: alexcherkasky@googlemail.com
Информация к новости
  • Просмотров: 4032
  • Автор: admin
  • Дата: 20-01-2014, 22:28
20-01-2014, 22:28

New Hope For People

Category: Blogs

New Hope For People

People Could Be Already Healed With My Anti-Cancer, Anti-Viral And
Anti-Autoimmune Inventions

Alexander Cherkasky


My name is Alexander Cherkasky, I am award-winning and
media-highlighted inventor and biologist and my story concerns various
fields including science, economy and general information relating to
all people, especially because my already published inventions can
help people. My inventions can heal. And a number of my inventions was
confirmed and my inventions are feasible and work.
The totality of facts described below is very near to everybody and
this totality of the facts disclosed below is unique. Thus I am
seeking for support for commercial implementation of my proposed
inventions, especially my anti-cancer, anti-viral, anti-autoimmune
inventions, inventions against metabolic disorders, inventions for
prolongation of cell life and extension of human life, renewal of
cells and tissues, regenerations, especially for neural regeneration,
and sequencing and diagnostic inventions, as well as inventions of
novel high-quality like-natural (like-as-natural) synthetic diamonds,
new lubricants and new materials, especially building materials. In
addition to seeking for partners for joint foundations of companies, I
am also seeking for support for establishing the new research
institute for further working on my solutions of biomedical problems.
Interesting is, that certain firms including Micromet, (who wanted to
be a ”future leader”), Merck in Darmstadt (Germany), Bayer, Apogenix,
Halcyon Molecular, Vaxil, Vecoy and ZS Genetics as well as the
organization Deutsches Krebsforschungszentrum (DKFZ, German Cancer
Research Center) are involved in plagiarism, in stealing my inventions
of anti-cancer fusion protein cures, anti-viral therapies and fast
genome sequencing systems.
Micromet, which was listed on the technology stock exchange NASDAQ (as
a public company with ticker symbol MITI) and which is now merged into
Amgen and renamed, ignored my two comments on Google Finance, in
Discussion Group about Micromet, although Micromet was a public
About Micromet’s plagiarism of my anticancer and antiautoimmune
inventions wrote also The New Rhein Newspaper (NRZ) Dusseldorf on
March 26, 2013, also because Micromet was a German company and I
immigrated from Ukraine to Germany in 1996 and I started to invent, to
create theoretical problem solutions (without lab, without working in
a laboratory).
Amgen denied to give any statement to NRW Dusseldorf about its deal
with Micromet, although Amgen is also a public company.
NRZ Dusseldorf wrote also about the plagiarist Apogenix, who stated
and just still continues to state that ”its” anticancer inventions are

I filed my first invention (of targeted genetically engineered
oncolytic viruses with recognizing receptors or antibodies) in the
year 1998, (my German patent application DE19818938), as I was student
at Goethe-Gymnasium (High School) in Dusseldorf.
The New Yorker Nobel Laureate Joshua Lederberg tried to claim this
invention in his US patent application US20040033584, but because I
had and have priority in Germany, which is priority worldwide,
Lederberg’s patent application was not new and not inventive.
The international patent application WO2006119449 for oncolytic
viruses of the American inventor David Curiel is also not novel and
not inventive because of my prior German patent publication
This my DE19818938 makes also the US patent application US20040247569
”Reduction in bacterial colonization by administering bacteriophage
compositions” of Intralytix, Inc., Baltimore, MD, US, (named inventors
are Glenn Morris, Alexander Sulakvelidze, Zemphira Alavidze (Tbilisi,
GE), Gary Pasternack and Torrey Brown; filed: December 2, 2003) not
new and not inventive.
In the years 1999 and 2000 I participated on the scientfic youth
competition ”Jugend forscht” (”Youth researches”) and presented my
inventions of novel anti-Alzheimer, anti-autoimmune and anti-cancer
fusion proteins. It evoked broad interest of press and about me and
inventions of mine reported Stern (The Star, March 25, 1999), Bild der
Wissenschaft (Picture of Science), Westdeutsche Zeitung (Westgerman
Newspaper), Neue Rhein Zeitung (New Rhein Newspaper), Rheinische Post
(Rhein Post) and other media.
”Jugend forscht” or ”Youth researches” was observed by the firm Bayer,
who made obstacles, but paid approximately 300 million euro to the
plagiarist Micromet for my invention presented at ”Youth researches”
in 2000!
For my novel selective anticancer fusion proteins I was awarded the
Bronze Medal ”For Outstanding Achievements” and the Honorary
Certificate of the largest international inventors competition in
Germany IENA (Ideas-Inventions-New Products) 2003 in Nuremberg.
By searches in the data banks of patent literature I discovered, that
a number of my inventions were used, were implemented and confirmed
with success by experiments and in certain cases my name and my
according patent documents were mentioned, refenced and in other cases
my name and my according patent documents were not referenced. The
cases, in which my name and according patent publications are not
referenced, although I have clearly documented priority and
inventorship, are either cases of plagiarism, because the totality of
joint features is obvious and plagiarists are not able to explain the
differences, that would make their ”inventions” new and inventive, or
are cases of insufficient searches in the data banks for patent
literature. Plagiarists are, in this context, persons, who are aware
of my according priority and inventorship, but in despite of this
knowledge, these persons continue to make false statements about
inventorship, but such statements are false, because no arguments or
no evidence were provided by these plagiarists.
Please read the following blogs to learn more:

http://plagiaristsdkfzandapogenix.blogspot.de/ and
http://plagiaristvecoy.blogspot.de/ .

Interestingly, the US company Halcyon Molecular cited my German
patent DE19937512 for fast genome sequencing in their US patent
US8153438, but Halcyon Molecular did not explained a difference, that
would make their patent , (issued by error of examiner and thus
rejectable after reexamination with the USPTO), new and inventive.
Errors of patent examiners can take place and this is obvious on
illustrative examples of issued US patents US7323440 (of Micromet) for
Fc-Autoantigen, especially Fc-AchR fusion proteins and US8007813
(based on the US patent applications US20070269449 and US20110305697
of Apogenix) for Fc-Receptor and Fc-Ligand fusion proteins, although
all Fc-Autoantigen, Fc-Receptor-Region, Fc-Receptor and Fc-Ligand
fusion proteins are disclosed in my prior patent publication
DE10160248. Because of this my DE10160248 both issued by error of
examiners US patents US7323440 of Micromet and US8007813 of Apogenix
can be reexamined and invalidated/rejected after reexamination by the
Because of my DE10160248 a number of patent documents/patent
applications are not new and not inventive. These published not new
and not inventive patent documents of others include the following:
EP2465524 (European patent application “Autoantibody production
inhibitor” of Nihon Pharmaceuticals in Tokyo (JP) describing
Fc-Autoantigen fusion proteins), WO2012159550 (“FGFR-Fc Fusion Protein
and Use thereof” of Yantai RC Biotechnogies Ltd (CN), Jianmin Fang
(CN), and Dong Li (CN)), NZ591970 (“Fusion Constructs and Use of Same
to Produce Antibodies with Increased Fc Receptor Binding Affinity and
Effector Function” of Pablo Umana, Peter Bruenker, Claudia Ferrara and
Tobias Suter at Roche Glycart AG, (also published as AU2012213963)),
MX2011011044 (“Antibody Fusion Proteins with Modified FcRN Binding
Sites” of Kin-Ming Lo (DE) and Pascal Andre Stein at Merck Patent
GmbH; especially claim 8 describing Fc Fragment), US20120093814
(“Fusion Proteins Comprising Canine FC Portions” of Keith Canada,
Sanjaya Singh, Xiangyang Zhu at Boehringer Ingelheim International
GmbH (DE)), NZ569702 (“Recombinant human EPO-Fc fusion proteins with
prolonged half-life and enhanced erythropoietic activity in vivo” of
Wang Houtao Du Yong et al at Novagen Holding Corp), KR20120028358
(“Truncated ACTR II B-Fc Fusion Proteins” of Seehra Jasbir (US) and
Kumar Ravindra (US) at Acceleron Pharma (US)), KR20120041139 (“Human
Interleukin-1 Receptor Antagonist-Hybrid Fc Fusion Protein” of Handkok
Pharmaceuticals Co Ltd (KR)) and US20120116056 (“Fc fusion proteins of
human growth hormone” of Sun Bill Nai-Chau (CN), Liou Ruey-Shyan (US)
et al).
But known are the cases in which examiners of patent offices done
searches and sent search reports to others, revealing with these
search reports, that my according prior patent documents made and make
claims and descriptions of others not novel and not inventive. For
example, my patent document DE19925052 was sent as search result for
the following patent publications of others: WO03070193 (”RNA
Interference Mediated Inhibition of HIV Gene Expression Using Short
Interfering Nucleic Acid (siNA)” of Sirna Therapeutics Inc. (US),
James McSwiggen (US), Leonid Beigelman (US) and Dennis Macejak (US),
also published as US20030175950, JP2006502694, EP1572128, CA2476394
and AU2003215345), EP1361891 (and WO02/066514 (PCT/EP02/01690))
(”Artifical Fusion Proteins with Reduced Immunogenicity” of Stephen
Gillies (US), Francis Carr (GB), Tim Gones (GB), Graham Carter (GB),
Anita Hamilton (GB), Stephen Williams (GB), Marian Haulon (GB), John
Watkins (GB), Matthew Baker (GB) and Jeffrey Way (US) at Merck Patent
GmbH (DE), (whreby Merck (Patent GmbH) replied to me in 1998 with deny
of cooperation, stating, that my proposed inventions are outside of
Merck’s research focus)), and EP1308516 (”Site-directed Recombinase
Fusion Proteins and Corresponding Polynucleotides, Vectors and Kits
and Their Uses for Site-directed DNA-Recombination” (Filed: October
24, 2001 and published on May 07, 2003) of Ferenc Mueller (DE), Uwe
Straehle (DE), Laszlo Tora (FR), Olasz Ferenc (HU), Janos Kiss (HU)
and Monika Szabo (HU) at Association pour le Developement de la
Recherche en Genetique Moleculaire in Paris). Plagiarism of Apogenix
and German Cancer Reserch Center DKFZ, confirmed by examiners of the
European Patent Office, was descibed in my blog
Examiners sent my DE10162867 as research result concerning the
international patent application WO2006045591 (PCT/EP2005/011441)
“Method and Constructs for Delivery Double Strauded RNA to Pest
Organisms” of Devgen NV (BE), Thierry Andre Olivier Bogaert (BE),
Richard Zwaal (BE), Geert Plaetnik (BE), Jan Octaaf de Kerpel (BE) and
Titus Jan Kaletta (BE).

I have developed programs of inventions including anti-cancer,
anti-autoimmune and anti-viral inventions.
My anticancer inventions (my program including my DE10350122,
DE19925052, DE19818938, DE19922406, DE10160248, DE10161899,
DE10161738, DE10161739, DE10162870, DE10162867, DE10350131,
DE102005028619, WO2006136892, WO2005040382, US20070106066 and
US20080200652) comprise inventions which allow to modify cancer cells
in order to normalize or combat them by acting on cytoskeleton,
cytoxically and/or by attracting T cells against target cells. In
addition, the effects of the anti-cancer antibodies which are already
on the market can be boosted by using my novel antibody-binding fusion
proteins. Damaged tissue can be regenerated with my inventions of
genetically modified cells expressing regeneration and genesis
proteins (my published German patent document DE19951694).
Because of my DE19925052, DE10161738 and DE10162870 covering novel
cytotoxic fusion proteins, the international patent application
WO2005116221 for immune suppressive hCTLA4-Ig (human cytotoxic T
lymphocyte antigen-Immunoglobulin)-fusion proteins (of Boryung Pharm
(KR))), is not new and not inventive.
Because of my DE19925052 (and DE10162870) the following publications
of others, disclosing fusion proteins containing cell specific
recognition domains in order to direct immune cells against target,
preferably cancer cells, or fusion proteins containing cell specific
and cytotoxic domains, (as well as spacers and protease-sensitive
sites), are not new and not inventive: WO2007002905 and EP1909832
(“Antibody-Immune Cell Ligand Fusion Protein for Cancer Therapy” of
Joseph Rosenblatt (US), Khaled Tolba (US) and Seung-Uon Shin (US) at
the University of Miami, (claim 18 discloses also “a monocyte
receptor, a B-cell surface receptor, and/or a T cell surface
receptor”), US20070071759 (“Antibody-Immune Cell Ligand Fusion Protein
for Cancer Therapy” of and Seung-Uon Shin, Joseph Rosenblatt, Khaled
Tolba at University of Miami), WO2006083961 (“Targeted Polypeptides”
(according to the abstract “for treating, preventing, and/or
monitoring therapy for a B-cell proliferative disorder”) of Michael
Rosenblum (US), Lawrence Cheung (US) and Mi-Ae Lyu (US) at Reserch and
Development Foundation (US); especially the claims 1-14, whereby
claims 4,5,10 and 14 describe cytotoxic B-cell targeting fusion
proteins), EP1217070, WO02052022 and AU2002229675 (“Selective
cytotoxic fusion proteins” of Felicia Rosenthal, Ou Cao and Peter
Kulmburg at Cellgenix Technologie Transfer; claim 27 reveals “a
polypeptide comprising…receptor (IL-2 receptor), …spacer
and…ribonuclease…”, (fusion proteins according to my DE19925052A1
comprise a receptor (claim 5), nuclease (claim 21), and hinge/spacer
domain (11 in Fig.1, Fig.3 and Fig.5)), claim 1 of EP1217070 reveals
“…a fusion protein which comprises a first polypeptide capable of
binding to a cell surface receptor present on human cells and a second
polypeptide which is toxic to a human cell after internalization of a
said second polypeptide by the human cell”; this fusion protein is
revealed in claims 5,12 and 13 and Fig.1 of my DE19925052A1),
US20110071214 (“Methods and Compositions for the Treatment of Cancer”
of Allen Gregory John (AU), (also published as WO2009137872 and
CA2760041), especially claims 1,4,83 (single-chained antibody) and 88
(haematological cancer)), US200600228404 (“Compositions and methods
for treatment of hypertrophic tissues” of Daniel Anderson (US), Robert
Langer, Robert Padera, Weidan Peng and Janet Sawicki; especially
claims 24,42 (cytotoxic or cytostatic polypeptide), 48 and 100
(site-specific recombinase), 104 (toxins), (the according claims in my
DE19925052A1 are 5,1 and 21)), US20120269837 (“Substance binding human
IgG Fc Receptor IIb (Fc gamma RIIb)” of the Nobelist Robert Huber
(DE), Peter Sondermann (CH), Kerstin Wendt (DE), Chiara Cabrele (DE)
and Luis Moroder (DE); especially the claims 57, 60 (polypeptide of
claim 57 conjugated to Fc [gamma] RIIb or Fc (gamma) RIIa) and 73
(cancer); (see claim 5 of my DE19925052A1), US20120269837 is also
published as WO2005051999, US2008014141, PT1709073 and PL1709073 and
is not novel also because of my DE10160248, DE10202191 and
DE102005028619), US20120107301 (“Method of treating autoimmune disease
by inducing antigen presentation by tolerance inducing antigen
presenting cells” of Katherine Bowdish (US), Anke Kretz-Rommel (US),
and Naveen Dakappagari at Alexion Pharma (US), especially the claims
8,13 (an antibody/peptide construct as in claim 8 further comprising a
toxin linked to the antibody) and 14 (tumor cell toxin); US20120107301
is also published as WO2004091543, US20060257412, US20060280679 and
NZ577166 and is also not novel because of my DE10133071), WO2007048022
(“Antibody-polypeptide Fusion Proteins and Methods for Producing and
Using Same” of Anke Kretz-Rommel et al at Alexion Pharma; this fact
was also described in my blog http://cherkaskyoffers.blogspot.com/)
and US20110275120 (“Fusion Proteins with Cleavable Spacers and Uses
Thereof” of Shen Wei-Chiang (US) et al at University of Southern
California; also published as WO2008121898, US20080299612, US7956158
(which can be invalidated and withdrawn after re-examination with the
USPTO), JP2010522570 and EP2139318, which are not novel because of
claim 12 and Fig. 3 (11 (hinge or spacer) and 9 (protease sensitive
site), 9 and 11 in combination) of my DE19925052A1).
My anti-autoimmune inventions (DE19822406, DE10133071 (making for
example MBP-toxin disclosed in WO2011101870 “Fusion Proteins for the
Treatment of Multiple Sclerosis and other Autoimmune Disorders” of
Kollipara Koteswara Rao (IN) at Transgene Biotek Ltd (IN) not novel
and not inventive), and DE10160248) allow to cleave and/or to
remove/neutralize autoantibodies and destroy autoreactive cells,
especially autoreactive B and T cells. And my DE19951694 allows to
regenerate tissue(s) destroyed especially by autoimmune attacks. With
my DE10202191 (Method for isolation and manipulation of single
molecules) still unknown autoantigens (from autoantigen candidates)
can be identified (0034-0038 of my DE10202191). Based on the
autoantigen information, new anti-autoimmune fusion proteins according
to my DE19822406, DE10133071 and DE10160248 can be made.

My anti-viral inventions allow to combat viruses both inside the cells
(by using my cell-specific, cell-penetrating and blocking nucleic acid
(antiviral ribozyme or antisense RNA)- transportating fusion proteins
disclosed in my German patent DE19925052) and outside the cells by
using my invention of cell-traps for viruses (my invention DE19951694
from the year 1999).
DE19951694 is a multipurpose invention comprising genetically modified
cells, especially immune cells, which express, for example neural or
neurogenesis proteins (like NGF, BDNF and/or other neural proteins)
for (in vivo) immune cell-induced neurogenesis and neural regeneration
(claims 5 and 16 and description, column 5, lines 30-36) and these
genetically modified cells, preferably immune cells, express also, or
alternatively, myelinogenesis proteins for immune cell-induced
myelination as well as myogenesis proteins for immune cell-induced
regeneration of muscles (claim 14) and/or angiogenesis proteins for
immune cell-induced angiogenesis (claim 3).
Cell-traps for viruses express antiviral antisense RNA and/or
antiviral ribozymes (for netralizing or cleavage/destruction of viral
RNA or DNA) and receptors for viral recognition, (like CD4 for HIV,
see claim 11 of my DE19951694).
Fusion proteins and fusion protein complexes according to DE19925052
can recognize targeted cells, (already infected cells or cells, that
can be infected), through the recognition region, penetrate them and
internalize into them through the mebrane penetration domains (MPD) or
cell penetration peptides (CPP) and bring into cells molecules,
especially antiviral RNA (such as specifically cleaving ribozyme(s) or
specifically neutralizing antisense RNA).
Fusion proteins containing any random protein (to be transported into
a cell) and MPD (membrane penetration domain) or CPP (for membrane
penetration and internalization) are covered by my published
DE19925052A1 (claims 4, 5, 6, 11 and 12), DE19951694 (claims 4 and 9)
and DE10162867 in the claim 1.

Because of my patent publication DE10162867 (claim 1 discloses fusion
proteins comprising, i.e. containing membrane penetration domain and
any other region/domain), as well as my DE19951694 and DE19925052, the
following publications of others, disclosing fusion proteins
containing MPD or CPP, are not novel and not inventive:US20120135021
(”Cell Penetrating Peptides and Its Use Fused to Biomolecules With
Therapeutic Action” of Torens Madrazo; Isis del Carmen; (Ciudad de la
Habana, CU); Guerra Vallespi; Maribel (CU); Granadillo Rodriguez;
Milaid; (CU); Reyes Acosta; Osvaldo (CU); Acevedo Casto; (CU) and
Boris Ernesto; (CU)), KR20020074282 (”Cell-Transducible Catalase
Fusion Protein And The Use Theseof” of Choi Su Young (KR) et al; also
published as KR100495139), KR20020010445 (”Cell-Transducing HIV-1
TAT-Superoxide Dismutase Fusion Protein And Use Theseof” of Choi Su
Young et al), WO2011084061 (”CPP (Cell Penetrating Peptide) and Its
Uses” of Universitair Medisch Centrum St. Radboud (NL), Roland Brock
(DE) and Wouter Verdurmen (NL); especially claim 4 (”the cationic CPP
is selected from the group consiting of: a cationic CPP
peptidomimetic, an arginine-rich CPP, a guanidine-rich CPP
peptidomimetic, a CPP derived from the human milk protein
lactoferrin”) and claim 9 (”the CPP is used in combination with
another cancer therapy”)), MX2008008548 (”Peptides Useful As
Cell-Penetrating Peptides” of Roland Brock (DE), Rainer Fischer (DE),
Mariola Fotin-Mleczek (DE), Hansjoerg Hufnagel and Norbert Windhab at
Evonik Roehm GmbH; also published as WO2007076904, US20100061932,
SI1966240, KR20080091120 and JP2009521908), KR20100001091 (”Fusion
Peptides Introducing Antibody into Cells, and Cellular Imaging and
Targeted Drug Delivery System Using the Same” of Chung Sang Jeon (KR)
et al, at Korea Research Institute of Bioscience), CN102311500
(”Antiviral fusion protein and application therof” of Lei Yang et al.
at Hangzhou Normal University), KR20100006939 (”Method for
Reprogramming of Cells Using Fusion Protein Delivery” of Korea
Research Institute of Bioscience and Biotechnology, (named ”inventors”
are Koo Deog Bon (KR), Kim Jang Hwan (KR), Cho Yee Sook (KR), Lee Seok
Jae (KR), and Park Tae Jung (KR))), and WO2010010112 (”Construct and
Method for the Internalization of Cargo Molecules Into a Cell” of DKFZ
Krebsforschungszentrum (DE), Markus Moosmeier (DE), Felix Hoppe-Seyler
(DE) and Karin Hoppe-Seyler (DE), also published as EP2147683).

Viral genetic information, i.e. viral nucleic acids inside cells can
be also specifically cleaved by selective fusion proteins containing
nuclease (enzyme for cleaving nucleic acids). This invention is
disclosed in my published German patent document DE10162870 (from the
year 2001). Because of my patent publications DE19925052 A1 (claims 5
and 21) and DE10162870, (claim 1 disloses also fusion proteins
containing nuclease and any other region or domain), the following
publications of others, disclosing fusion proteins containing
nuclease, are not novel and not inventive: WO2012168304 (”Protein
Having Nuclease Activing, Fusion Proteins and Uses Thereof” of
Helmholtz Zentrum Muenchen (Helmholtz Zentrum Muenchen-Deutsches
Forschungszentrum Fuer Gesundheit und Umwelt GmbH (DE)) and Ralf
Kuehn (DE)), WO2012168910 (”Nuclease Fusion Protein And Use Thereof”
of BASF Plant Science Co GmbH (DE), BASF China Co LTD (CN), Ines
Fonfara (DE), Wolfgang Wende (DE) and Alfred Pingoud (DE)),
WO2012169916 (”Sequence-Specific Engineered Ribonuclease H and The
Method for Determining the Sequence Preference of DNA-RNA Hybrid
Binding Proteins” of Miedzynarodowy Inst. Biolog. Molekularnej i
Komorkowej (PL), Janusz Marek Bujnicki (PL) et al; this WO2012169916
is also not novel because of my DE10162867 covering nucleic acid
binding fusion proteins), US20090123972 (”Staphylococcal nuclease
fusion proteins for the production of recombinant peptides” of Canada
Natural Research Council, (named inventors are Su Zhengding (CA) and
Ni Feng (CA)), WO2011159369 (”Nuclease Activity of Tal Effector and
Foki Fusion Protein” of University of Iowa Research Foundation (US),
named inventors are Yang Bing (US) and Li Ting (US)), WO2012168304
(”Protein Having Nuclease Activity, Fusion Proteins and Uses Thereof”
of Helmholtz Zentrum Muenchen (DE) and Ralf Kuehn (DE)) and
WO2011154393 (”Fusion Proteins Comprising A DNA-Binding Domain of A
Tal Effector Protein And A Non-Specific Cleavage Domain Of A
Restriction Nuclease And Their Use” of Helmholtz Zentrum Muenchen
(DE), Ralf Kuehn (DE) et al; also not novel because of my DE10162867,
claim 3 (disclosing fusion proteins containing DNA binding